JP2002501885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002501885A5 JP2002501885A5 JP2000529227A JP2000529227A JP2002501885A5 JP 2002501885 A5 JP2002501885 A5 JP 2002501885A5 JP 2000529227 A JP2000529227 A JP 2000529227A JP 2000529227 A JP2000529227 A JP 2000529227A JP 2002501885 A5 JP2002501885 A5 JP 2002501885A5
- Authority
- JP
- Japan
- Prior art keywords
- aerosol
- surfactant
- drug
- weight
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000443 aerosol Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 18
- 150000003904 phospholipids Chemical class 0.000 description 16
- 239000004094 surface-active agent Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 13
- 239000003380 propellant Substances 0.000 description 12
- 239000011859 microparticle Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 8
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 229940071648 metered dose inhaler Drugs 0.000 description 3
- 239000013081 microcrystal Substances 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
Description
【特許請求の範囲】
【請求項1】膜形成性両親媒性脂質で被覆され、1,1,1,2-テトラフルオロエタン(HFA 134a)または1,1,1,2,3,3,3-ヘプタフルオロプロパン(HFA 227)プロペラント中に分散されている粒度範囲0.1〜10ミクロンの薬物微粒子の安定化された粒子から本質的に構成されるエーロゾル製剤。
【請求項2】両親媒性脂質がリン脂質である請求項1に記載のエーロゾル製剤。
【請求項3】リン脂質被覆が少なくとも一種の界面活性剤も含有する請求項2に記載のエーロゾル製剤。
【請求項4】一種またはそれ以上の膜形成性リン脂質と少なくとも一種の界面活性剤で被覆され、HFA 134a または HFA 227プロペラント中に分散されている平均粒度範囲0.1〜10ミクロンの薬物微結晶から本質的に構成されるエーロゾル製剤であって、被覆した薬物微粒子の密度がプロペラントの密度と実質的に同じであり、薬物微粒子上の被覆の量が薬物の重量を基準に0.1%を超え200%未満であるエーロゾル製剤。
【請求項5】プロペラントが製剤の少なくとも70重量%の割合を占める請求項1または4に記載のエーロゾル製剤。
【請求項6】薬物が製剤の5重量%未満の割合を占める請求項5に記載のエーロゾル製剤。
【請求項7】界面活性剤に対するリン脂質の重量比が0.04〜25の範囲である請求項3または4に記載のエーロゾル製剤。
【請求項8】リン脂質が製剤の20重量%未満の割合を占める請求項2または4に記載のエーロゾル。
【請求項9】界面活性剤が製剤の20重量%未満の割合を占める請求項3に記載のエーロゾル。
【請求項1】膜形成性両親媒性脂質で被覆され、1,1,1,2-テトラフルオロエタン(HFA 134a)または1,1,1,2,3,3,3-ヘプタフルオロプロパン(HFA 227)プロペラント中に分散されている粒度範囲0.1〜10ミクロンの薬物微粒子の安定化された粒子から本質的に構成されるエーロゾル製剤。
【請求項2】両親媒性脂質がリン脂質である請求項1に記載のエーロゾル製剤。
【請求項3】リン脂質被覆が少なくとも一種の界面活性剤も含有する請求項2に記載のエーロゾル製剤。
【請求項4】一種またはそれ以上の膜形成性リン脂質と少なくとも一種の界面活性剤で被覆され、HFA 134a または HFA 227プロペラント中に分散されている平均粒度範囲0.1〜10ミクロンの薬物微結晶から本質的に構成されるエーロゾル製剤であって、被覆した薬物微粒子の密度がプロペラントの密度と実質的に同じであり、薬物微粒子上の被覆の量が薬物の重量を基準に0.1%を超え200%未満であるエーロゾル製剤。
【請求項5】プロペラントが製剤の少なくとも70重量%の割合を占める請求項1または4に記載のエーロゾル製剤。
【請求項6】薬物が製剤の5重量%未満の割合を占める請求項5に記載のエーロゾル製剤。
【請求項7】界面活性剤に対するリン脂質の重量比が0.04〜25の範囲である請求項3または4に記載のエーロゾル製剤。
【請求項8】リン脂質が製剤の20重量%未満の割合を占める請求項2または4に記載のエーロゾル。
【請求項9】界面活性剤が製剤の20重量%未満の割合を占める請求項3に記載のエーロゾル。
[2] 両親媒性脂質がリン脂質である1に記載のエーロゾル製剤。
[3] リン脂質被覆が少なくとも一種の界面活性剤も含有する2に記載のエーロゾル製剤。
[4] 一種またはそれ以上の膜形成性リン脂質と少なくとも一種の界面活性剤で被覆され、HFA 134a または HFA 227プロペラント中に分散されている平均粒度範囲0.1〜10ミクロンの薬物微結晶から本質的に構成されるエーロゾル製剤であって、被覆した薬物微粒子の密度がプロペラントの密度と実質的に同じであり、薬物微粒子上の被覆の量が薬物の重量を基準に0.1%を超え200%未満であるエーロゾル製剤。
[5] プロペラントが製剤の少なくとも70重量%の割合を占める1または4に記載のエーロゾル製剤。
[6] プロペラントが製剤の少なくとも90重量%の割合を占める5に記載のエーロゾル製剤。
[7] 薬物が製剤の5重量%未満の割合を占める5に記載のエーロゾル製剤。
[8] 界面活性剤に対するリン脂質の重量比が0.04〜25の範囲である3または4に記載のエーロゾル製剤。
[9] 界面活性剤に対するリン脂質の重量比が0.02〜50の範囲である3または4に記載のエーロゾル製剤。
[10] 界面活性剤に対するリン脂質の比が0.01〜100;好ましくは0.02〜50;より好ましくは0.04〜25の範囲である。
[11] リン脂質が製剤の20重量%未満の割合を占める2または4に記載のエーロゾル。
[12] リン脂質が製剤の5重量%未満の割合を占める2に記載のエーロゾル。
[13] 界面活性剤が製剤の20重量%未満の割合を占める3に記載のエーロゾル。
[14] 界面活性剤が製剤の5重量%未満の割合を占める3または4に記載のエーロゾル。
[15] HFA134a、HFA227またはそれらの混合物から選択される非水性プロペラント中に懸濁している平均粒度が0.1〜10ミクロンの薬物微粒子からなるエーロゾル製剤を含有する定量投与用吸入器であって、前記薬物微粒子が膜形成性両親媒脂質でおよび場合によりさらに界面活性剤で被覆され、凝集に対し安定化されている定量投与用吸入器。
[16] 薬物粒子がリン脂質で被覆される15に記載の吸入器。
[17] リン脂質被覆が界面活性剤も含有する15または16に記載の吸入器。
[18] リン脂質と少なくとも一種の界面活性剤との混合物で被覆され、HFA 134a または HFA 227プロペラント中に分散されている平均粒度範囲0.1〜10ミクロンの薬物微粒子から本質的に構成されるエーロゾル製剤を含有する定量投与用吸入器であって、被覆した薬物微結晶の密度がプロペラントの密度と実質的に同じであり、薬物微粒子上の被覆の量が薬物の重量を基準に0.1%を超え200%未満であるエーロゾル製剤。
[19] 膜形成性両親媒脂質と場合により界面活性剤とで被覆され、上気道または低気道に送達するための薬学的に許容できるキャリアー中に分散されている粒度範囲が0.1〜10ミクロンの薬物微粒子。
[20] 上気道または下気道に送達するための、膜形成性両親媒脂質と場合により界面活性剤とで被覆され、0.1〜10ミクロンの粒度範囲の薬物微粒子から本質的に構成される乾燥粉末。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/016,265 | 1998-01-30 | ||
US09/016,265 US6086376A (en) | 1998-01-30 | 1998-01-30 | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
PCT/US1998/027922 WO1999038493A1 (en) | 1998-01-30 | 1998-12-30 | Microparticle inhalation formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010128713A Division JP2010248206A (ja) | 1998-01-30 | 2010-06-04 | 微粒子吸入用製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002501885A JP2002501885A (ja) | 2002-01-22 |
JP2002501885A5 true JP2002501885A5 (ja) | 2006-02-23 |
Family
ID=21776235
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000529227A Withdrawn JP2002501885A (ja) | 1998-01-30 | 1998-12-30 | 微粒子吸入用製剤 |
JP2010128713A Pending JP2010248206A (ja) | 1998-01-30 | 2010-06-04 | 微粒子吸入用製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010128713A Pending JP2010248206A (ja) | 1998-01-30 | 2010-06-04 | 微粒子吸入用製剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6086376A (ja) |
EP (1) | EP1051154A1 (ja) |
JP (2) | JP2002501885A (ja) |
KR (1) | KR20010040402A (ja) |
CN (1) | CN1155367C (ja) |
AU (1) | AU756464B2 (ja) |
CA (1) | CA2319100C (ja) |
IL (1) | IL137472A (ja) |
SE (1) | SE0002643L (ja) |
WO (1) | WO1999038493A1 (ja) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0810853B1 (en) | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
JP2002516267A (ja) | 1998-05-29 | 2002-06-04 | アールティーピー・ファーマ・インコーポレーテッド | 熱的に保護された微粒子組成物及びその最終蒸気滅菌 |
MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
KR20010073232A (ko) | 1998-11-20 | 2001-07-31 | 추후제출 | 분산성 인지질로 안정화된 마이크로입자 |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
IL148685A0 (en) * | 1999-09-21 | 2002-09-12 | Rtp Pharma Inc | Surface modified particulate compositions of biologically active substances |
US6962151B1 (en) * | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
US6645467B2 (en) * | 1999-11-28 | 2003-11-11 | Scientific Development And Research, Inc. | Composition and method for decreasing upper respiratory airway resistance |
IT1317720B1 (it) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
GB0016876D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
US20040081627A1 (en) * | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
ES2296831T3 (es) * | 2000-11-30 | 2008-05-01 | Vectura Limited | Metodo para preparar microparticulas para usar en composiciones farmaceuticas para inhalacion. |
PT1920763E (pt) * | 2000-11-30 | 2014-06-25 | Vectura Ltd | Composições farmacêuticas para inalação |
EP1337239B2 (en) | 2000-11-30 | 2015-11-25 | Vectura Limited | Particles for use in a pharmaceutical composition |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US7193084B2 (en) * | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US20030096013A1 (en) * | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
US6869617B2 (en) | 2000-12-22 | 2005-03-22 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) * | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
ATE375142T1 (de) * | 2001-03-30 | 2007-10-15 | Jagotec Ag | Medizinische aerosolformulierungen |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
BR0212833A (pt) | 2001-09-26 | 2004-10-13 | Baxter Int | Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
PT1458360E (pt) | 2001-12-19 | 2011-07-13 | Novartis Ag | Derivados de indole como agonistas do recetor s1p1 |
US20030178022A1 (en) * | 2001-12-21 | 2003-09-25 | Chiesi Farmaceutici S.P.A. | Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators |
PT3536344T (pt) * | 2002-03-01 | 2020-03-26 | Chiesi Farm Spa | Formulação superfina de formoterol |
JP3620842B2 (ja) * | 2002-12-25 | 2005-02-16 | 孝之 阿部 | 多角バレルスパッタ装置、多角バレルスパッタ方法及びそれにより形成された被覆微粒子、被覆微粒子の製造方法 |
US7511079B2 (en) * | 2003-03-24 | 2009-03-31 | Baxter International Inc. | Methods and apparatuses for the comminution and stabilization of small particles |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
DE10347994A1 (de) * | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
US20050121025A1 (en) * | 2003-12-04 | 2005-06-09 | Gamard Stephan C.F. | Portable gas operating inhaler |
TWI262798B (en) * | 2003-12-31 | 2006-10-01 | Ind Tech Res Inst | Liposome and drug deliver system |
EP1711163A2 (en) * | 2004-02-05 | 2006-10-18 | Baxter International Inc. | Dispersions prepared by use of self-stabilizing agents |
US8082735B2 (en) * | 2005-04-06 | 2011-12-27 | Massachusetts Institute Of Technology | Optimized fuel management system for direct injection ethanol enhancement of gasoline engines |
EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
US8367734B1 (en) | 2005-08-11 | 2013-02-05 | Amphastar Pharmaceuticals Inc. | Stable epinephrine suspension formulation with high inhalation delivery efficiency |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
WO2008152398A2 (en) * | 2007-06-14 | 2008-12-18 | Cipla Limited | Formulations for inhalation |
GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
DK2400950T3 (da) | 2009-02-26 | 2019-07-29 | Glaxo Group Ltd | Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
AU2011320159B2 (en) | 2010-10-29 | 2016-12-22 | Western University Of Health Sciences | Ternary mixture formulations |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
GB201118232D0 (en) | 2011-10-21 | 2011-12-07 | M W Encap Ltd | Pharmaceutical composition |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
JP6417181B2 (ja) * | 2014-10-10 | 2018-10-31 | 学校法人神奈川大学 | エアゾール作製用乳化組成物、及びエアゾール剤 |
KR20230130175A (ko) * | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
WO2017156380A1 (en) * | 2016-03-10 | 2017-09-14 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CA3078723A1 (en) | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
US10315836B2 (en) * | 2017-10-19 | 2019-06-11 | Matthew James ZABLOSKI | Methods, uses, and apparatus for presenting and storing objects |
AU2018378832B9 (en) | 2017-12-07 | 2021-05-27 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
US20210353650A1 (en) * | 2020-05-18 | 2021-11-18 | Cai Gu Huang | Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7708731A (nl) * | 1976-08-13 | 1978-02-15 | Montedison Spa | Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen. |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8908250D0 (en) * | 1989-04-12 | 1989-05-24 | Fisons Plc | Formulations |
GB8921222D0 (en) * | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
GB9002327D0 (en) * | 1990-02-02 | 1990-04-04 | Univ Sheffield | Optical elements |
DE4003272A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
US5118494A (en) * | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5126123A (en) * | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
CA2094266C (en) * | 1990-10-18 | 1999-06-01 | Robert K. Schultz | Aerosol formulations of beclomethasone-17,21-dipropionate |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5182097A (en) * | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
PT656207E (pt) * | 1991-06-10 | 2001-11-30 | Schering Corp | Formulacoes de aerossois sem clorofluorocarbonetos |
IL103238A (en) * | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressed aerosol preparations |
DE4132677C2 (de) * | 1991-10-01 | 1995-08-24 | Braun Melsungen Ag | Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung |
US5674471A (en) * | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
ATE171865T1 (de) * | 1991-12-12 | 1998-10-15 | Glaxo Group Ltd | Arzneimittel |
US5683676A (en) * | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
US5202110A (en) * | 1992-01-22 | 1993-04-13 | Virginia Commonwealth University | Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
EP0689423B1 (en) * | 1993-03-17 | 1997-09-17 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing a diol-diacid derived dispersing aid |
US5492688A (en) * | 1993-04-28 | 1996-02-20 | The Center For Innovative Technology | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent |
DE4323636A1 (de) * | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
US5635159A (en) * | 1994-08-26 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
GB9425160D0 (en) * | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
MX9704550A (es) * | 1994-12-22 | 1997-10-31 | Astra Ab | Formulaciones de medicamentos en aerosol. |
US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
CA2217954C (en) * | 1995-04-14 | 2005-02-15 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
SK284448B6 (sk) * | 1995-04-14 | 2005-04-01 | Glaxo Wellcome Inc. | Merací dávkovací inhalátor |
TR199701167T1 (xx) * | 1995-04-14 | 1998-03-21 | Glaxo Wellcome Inc. | Albuterol i�in �l��lm�� doz inhaleri. |
US5635161A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
GB9610341D0 (en) * | 1996-05-17 | 1996-07-24 | Andaris Ltd | Formulation for inhalation |
-
1998
- 1998-01-30 US US09/016,265 patent/US6086376A/en not_active Expired - Lifetime
- 1998-12-30 CA CA002319100A patent/CA2319100C/en not_active Expired - Fee Related
- 1998-12-30 CN CNB988133849A patent/CN1155367C/zh not_active Expired - Fee Related
- 1998-12-30 WO PCT/US1998/027922 patent/WO1999038493A1/en not_active Application Discontinuation
- 1998-12-30 IL IL13747298A patent/IL137472A/xx not_active IP Right Cessation
- 1998-12-30 AU AU20244/99A patent/AU756464B2/en not_active Ceased
- 1998-12-30 KR KR1020007008094A patent/KR20010040402A/ko not_active Application Discontinuation
- 1998-12-30 JP JP2000529227A patent/JP2002501885A/ja not_active Withdrawn
- 1998-12-30 EP EP98965051A patent/EP1051154A1/en not_active Ceased
-
2000
- 2000-07-13 SE SE0002643A patent/SE0002643L/xx not_active Application Discontinuation
-
2010
- 2010-06-04 JP JP2010128713A patent/JP2010248206A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002501885A5 (ja) | ||
JP2786493B2 (ja) | 医薬エアゾール製剤 | |
JP2915574B2 (ja) | 医療用エアロゾル製剤 | |
JP5170789B2 (ja) | 喘息治療用の製薬組成物 | |
EP0904056B1 (en) | Process and device for inhalation of particulate medicaments | |
TWI546094B (zh) | 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 | |
JP3056784B2 (ja) | エアゾール医薬製剤 | |
US5439670A (en) | Medicinal aerosol formulations | |
KR100546239B1 (ko) | 약제 에어로졸 조성물 | |
JP2002530316A (ja) | Hfa227およびhfa137を含有する製薬学的エアゾル組成物 | |
JPH10510521A (ja) | エアゾール処方物用噴射剤混合物 | |
JP2002541183A (ja) | 医薬用エアゾール製剤 | |
AU2002313828A1 (en) | Pharmaceutical compositions for the treatment of asthma | |
JP2002501885A (ja) | 微粒子吸入用製剤 | |
JP2001501209A (ja) | ブデソニドを含有する医療用エアゾル組成物 | |
AU760537B2 (en) | Particulate delivery systems and methods of use | |
WO1998041191A1 (fr) | Preparation pour aerosol | |
AU774250B2 (en) | Pharmaceutical aerosol composition | |
CN105106200A (zh) | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 | |
NZ243056A (en) | Aerosol formulation containing a medicament, tetrafluoroethane and isopropyl myristate | |
CA2303601A1 (en) | Medicinal aerosol formulations |